InflammX' Investors
Domain Associates, L.L.C.
Founded in 1985, Domain was one of the first venture capital firms to exclusively invest in the life sciences sector. Domain has been involved in the formation of more than 260 companies. Today, with more than $2.8 billion in capital raised, Domain is a proven healthcare venture capital leader with solid investment returns from companies built to advance human health.
Domain’s three major investment segments are pharmaceuticals, diagnostics, and medical devices, while additional areas additional areas of interest include biomaterials, bioinstrumentation, and evolving sectors of the life sciences industry and technologies addressing specific healthcare issues. Domain is dedicated to creating trust, credibility, and value in our business relationships and to establishing long-term partnerships with our entrepreneurs, investors, and industry collaborators. Domain has a history of retaining investors across multiple funds and attracting successful entrepreneurs to build companies with Domain and approach healthcare venture capital from a service standpoint, demonstrating reliability and performance that earns and justifies trust.
RMI PaRTNERS
RMI Partners is a venture company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe, RMI Partners is one of the largest investors in life sciences. The company makes global investments in a variety of therapeutic areas.
RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.
RMI Partners is currently managing the venture fund RusnanoMedInvest (RMI, a subsidiary of JSC RUSNANO), which was created in 2012 to develop innovative projects in the field of medicine and pharmaceutics. RMI’s portfolio includes companies from Eastern Europe, USA, UK and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies, many of which successfully completed an initial public offering (IPO) on NASDAQ, or were purchased by strategic buyers.
RMI Partners is a member of Invest Europe, the association which is representing Europe’s private equity, venture capital and infrastructure sectors.